Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer

Background. No predictive or prognostic biomarker is available for patients with locally advanced rectal cancer (LARC) undergoing perioperative chemoradiotherapy (CRT). Members of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases EGFR (HER1, ERBB1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4) are therapeutic targets in several cancers. The analysis was performed to assess expression levels and study the potential prognostic impact for disease-free and overall survival in patients with LARC. Patients and Methods. ERBB1–4 mRNA expression and tumor proliferation using Ki-67 (MKI67) mRNA were evaluated using RT-quantitative PCR in paraffin-embedded tumor samples from 86 patients (median age: 63) treated with capecitabine or 5-fluorouracil-based CRT within a phase 3 clinical trial. Results. A positive correlation of HER4 and HER2, HER3 and HER2, and HER4 and HER3 with each other was observed. Patients with high mRNA expression of ERBB1 (EGFR, HER1) had significantly increased risk for recurrence and death. Patients with high mRNA expression of MKI67 had reduced risk for relapse. Conclusion. This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy.

[1]  R. Labianca,et al.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study , 2015, Modern Pathology.

[2]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[3]  H. Gogas,et al.  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study , 2015, Journal of Translational Medicine.

[4]  V. Torri,et al.  Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. , 2015 .

[5]  Helen M. Moore,et al.  Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue , 2014, Oncotarget.

[6]  Joon-Oh Park,et al.  Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. , 2014, The Lancet. Oncology.

[7]  B. Heppner,et al.  HER2/neu testing in primary colorectal carcinoma , 2014, British Journal of Cancer.

[8]  B. S. Sørensen,et al.  Optimal Reference Genes for Normalization of qRT-PCR Data from Archival Formalin-fixed, Paraffin-embedded Breast Tumors Controlling for Tumor Cell Content and Decay of mRNA , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  T. Beißbarth,et al.  Frequency of HER-2 Positivity in Rectal Cancer and Prognosis , 2013, The American journal of surgical pathology.

[10]  A. Schneeweiss,et al.  Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer , 2012 .

[11]  Charles J. Bechert,et al.  Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma , 2012, Clinical Cancer Research.

[12]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[13]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[14]  M. Ychou,et al.  EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer , 2011, International journal of cancer.

[15]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[16]  Y. Toiyama,et al.  Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  D. Sargent,et al.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Uwe Rogel,et al.  RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.

[19]  J. Monson,et al.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.

[20]  Hiroaki Sakurai,et al.  Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells , 2008, International journal of cancer.

[21]  I. Fidler,et al.  Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. , 2008, The American journal of pathology.

[22]  D. Aust,et al.  Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. , 2008, World journal of gastroenterology.

[23]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Collette,et al.  Chemotherapy with Preoperative Radiotherapy in Rectal Cancer , 2007 .

[25]  H. Johansson,et al.  Impact of a surgical training programme on rectal cancer outcomes in Stockholm , 2005, The British journal of surgery.

[26]  J. Tepper,et al.  Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Tony Hunter,et al.  Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[28]  S. Ethier,et al.  ERBB-2 overexpression confers PI 3 ′ kinase-dependent invasion capacity on human mammary epithelial cells , 2000, British Journal of Cancer.

[29]  N. Haites,et al.  Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. , 1996, European journal of cancer.

[30]  H. Wieand,et al.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. , 1994, The New England journal of medicine.

[31]  M. Choti,et al.  Rectal cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  C. Bucana,et al.  Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Fitzgibbons,et al.  Patterns of recurrence after curative resection of carcinoma of the colon and rectum. , 1992, Surgery, gynecology & obstetrics.